11-21 | Latest UNAIDS treatment numbers show progress, but funding crunch is major threat
11-21 | Latest UNAIDS treatment numbers show progress, but funding crunch is major threat
9-9 | The medical humanitarian organisation Médecins Sans Frontières (MSF) is deeply concerned about the implications of the current economic crisis in Swaziland on people living with HIV/AIDS. To pre-empt stock ruptures, which are already affecting patients, MSF has supplied a contingency stock of antiretroviral (ARV) drugs that will serve some 18,000 AIDS patients in its project areas for at least one month.
9-5 | Novartis will go before the Indian Supreme Court tomorrow in the latest attempt by the Swiss multinational pharmaceutical company to undermine a key public health safeguard in Indian patent law specifically designed to prevent drug companies from abusively patenting known medicines. If successful, the move would have a devastating impact on access to affordable medicines across the developing world, according to international humanitarian medical organisation Médecins Sans Frontières (MSF).
7-12 | Excluded countries should be ready to issue compulsory licences to access needed drugs An agreement announced today by pharmaceutical company Gilead to licence several HIV/AIDS drugs to the Medicines Patent Pool could improve access to medicines for patients, but excludes several countries with large numbers of people living with HIV, the international medical humanitarian organisation Médecins Sans Frontières (MSF) said today.